Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix

Pathology Research and Practice

Volumn 207, Issue 1, 2011, Pages 37-42

  Missaoui, Nabiha ^a,b,c   Hmissa, Sihem ^a,c   Trabelsi, Amel ^c   Traoré, Cheick ^d   Mokni, Moncef ^c   Dante, Robert ^b   Frappart, Lucien ^b,d  

^a Medicine Faculty   (Tunisia)

^b CENTRE LÉON BÉRARD   (France)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Biomarker; Cancer; Diagnosis; DNA hypermethylation; Uterine cervix

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE 1; H CADHERIN; MOLECULAR MARKER; PROTEIN; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRECANCER; PROMOTER REGION; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

APOPTOSIS REGULATORY PROTEINS; BIOPSY; CADHERINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; TWIST TRANSCRIPTION FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 78650247441     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.11.001     Document Type: Article

References (49)

1. Benedet J.L. Progress in gynecologic cancer detection and treatment. Int. J. Gynaecol. Obstet. 2000, 70:135-147.
2. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 2005, 23:2903-2910.
3. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J. 2003, 22:2318-2323.
4. Cancer Incidence in Five Continents 2007, vol. IX. IARC Scientific Publications, Lyon, No. 160.
5. Dell G., Gaston K. Human papillomaviruses and their role in cervical cancer. Cell. Mol. Life Sci. 2001, 58:1923-1942.
6. Dong S.M., Kim H.S., Rha S.H., Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 2001, 7:1982-1986.
7. Doorn van R., Zoutman W.H., Dijkman R., et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J. Clin. Oncol. 2005, 23:3886-3898.
8. Dyson N., Howley P.M., Münger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
9. Esteller M., Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 2002, 196:1-7.
10. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
11. Feng Q., Balasubramanian A., Hawes S.E., et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J. Natl. Cancer Inst. 2005, 97:273-282.
12. Feng Q., Hawes S.E., Stern J.E., et al. Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1178-1184.
13. Florl A.R., Steinhoff C., Müller M., et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 2004, 91:985-994.
14. Henken F.E., Wilting S.M., Overmeer R.M., et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br. J. Cancer 2007, 97:1457-1464.
15. Hiraga J., Kinoshita T., Ohno T., et al. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int. J. Hematol. 2006, 84:248-255.
16. Hoque M.O., Feng Q., Toure P., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 2006, 24:4263-4269.
17. Husemann Y., Geigl J.B., Schubert F., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
18. Inbal B., Cohen O., Polak-Charcon S., et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997, 390:180-184.
19. Jeong D.H., Youm M.Y., Kim Y.N., et al. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int. J. Gynecol. Cancer 2006, 16:1234-1240.
20. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
21. Kahn S.L., Ronnett B.M., Gravitt P.E., Gustafson K.S. Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer 2008, 114:57-64.
22. Kang S., Kim W.J., Kang G.H., et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Cancer 2006, 118:2168-2171.
23. Kang S., Kim J.W., Kang G.H., et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol. Oncol. 2005, 96:173-180.
24. Maestro R., Dei Tos A.P., Hamamori Y., et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13:2207-2217.
25. Magdinier F., Billard L.M., Wittmann G., et al. Regional methylation of the end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J. 2000, 14:1585-1594.
26. Mironchik Y., Winnard P.T., Vesuna F., et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005, 65:10801-10809.
27. Missaoui N., Trabelsi A., Hmissa S., et al. p16INK4A overexpression in precancerous and cancerous lesions of the uterine cervix in Tunisian women. Pathol. Res. Pract. 2010, 206:550-555.
28. Müller H.M., Fiegl H., Widschwendter A., Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Ann. N. Y. Acad. Sci. 2004, 1022:44-49.
29. Narayan G., Arias-Pulido H., Koul S., et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 2003, 2:24.
30. Oikonomou P., Messinis I., Tsezou A. DNA methylation is not likely to be responsible for hTERT expression in premalignant cervical lesions. Exp. Biol. Med. 2007, 232:881-886.
31. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993, 12:186-192.
32. Perrin D., Ballestar E., Fraga M.F., et al. Specific hypermethylation of LINE-1 elements during abnormal overgrowth and differentiation of human placenta. Oncogene 2007, 26:2518-2524.
33. Reesink-Peters N., Wisman G.B.A., Jéronimo C., et al. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol. Cancer Res. 2004, 2:289-295.
34. Shivapurkar N., Sherman M.E., Stastny V., et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol. Oncol. 2007, 107:549-553.
35. Snijders P.J., van den Brule A.J., Schrijnemakers H.F., et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J. Gen. Virol. 1990, 71:173-181.
36. Tumours of the Breast and Female Genital Organs 2003, IARC, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
37. Terra A.P., Murta E.F., Maluf P.J., et al. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori 2007, 93:572-579.
38. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
39. Tost J. DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol. Biotechnol. 2010, 44:71-81.
40. Toyooka K.O., Toyooka S., Virmani A.K., et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001, 61:4556-4560.
41. Virmani A.K., Muller C., Rathi A.S., et al. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 2001, 7:584-589.
42. Wentzensen N., Sherman M.E., Schiffman M., Wang S.S. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 2009, 112:293-299.
43. Widschwendter A., Gattringer C., Ivarsson L., et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin. Cancer Res. 2004, 10:3396-3400.
44. Widschwendter A., Ivarsson L., Blassnig A., et al. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int. J. Cancer 2004, 109:163-166.
45. Widschwendter A., Müller H.M., Fiegl H., et al. DNA methylation in serum and tumors of cervical cancer patients. Clin. Cancer Res. 2004, 10:565-571.
46. Wisman G.B., Nijhuis E.R., Hoque M.O., et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int. J. Cancer 2006, 119:1908-1914.
47. Yang J., Mani S.A., Donaher J.L., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
48. Yang H.J., Liu V.W., Wang Y., Tsang P.C., Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006, 6:212.
49. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.